Post-Earnings Marketing Summary: Growing Confidence in China's Healthcare Innovation Cycle

Key Takeaways: Investors maintain a high level of attention on the theme of healthcare innovation in China, with CXO (Contract Research and Manufacturing Organizations), biotechnology, and AIDD (AI-driven Drug Discovery) as the core focus. During roadshows in Singapore and Hong Kong in early September, JPMorgan engaged with investors from approximately 25 institutions. Investors held a constructive view on the three themes closely tied to innovation: CXO, AIDD, and biotechnology. Meanwhile, interest in medical technology (Medtech) is growing as a new opportunity arising from sector rotation. CXO garnered the most discussion due to its generally better-than-expected performance in the first half of the year and upward revisions to guidance, with investors increasing their...

CSOPSep 10 12:05

Mainland China's 2026 National Reimbursement Drug List is expected to be released in November.

According to CCTV, the National Healthcare Security Administration organized on-site price negotiations for the 2026 National Reimbursement Drug List (NRDL) from September 5 to 8. Over 100 domestic and foreign enterprises participated in person, with 124 drugs not currently on the list shortlisted for negotiation. Innovative medicines in key areas of public concern, including oncology, rare diseases, chronic conditions, and pediatric treatments, were included in the negotiations and are expected to be added to the reimbursement list. Concurrently, adjustments to the innovative drug catalog for commercial health insurance were carried out, with 12 drugs undergoing on-site price consultations. The 2026 National Reimbursement Drug List and the Commercial Insurance Innovative Drug Catalog are scheduled for release in November this year, taking effect on January 1, 2027.

AASTOCKSSep 9 14:19

CLSA: China’s Innovative Drug Sector Returns to Alpha Dominance; Macro Volatility May Present Buying Opportunities

A report by CLSA indicates that China’s innovative drug sector is returning to a market driven primarily by company fundamentals and stock-specific alpha, with the influence of company-specific fundamentals—particularly business development (BD) and Phase III clinical progress—rising relative to macro factors (beta). Attribution analysis by the bank shows that the explanatory power of fundamentals for pharmaceutical stock price movements reached 82.7% from 2015 to 2021, fell to approximately 32.7% from 2021 to 2024, and has rebounded to over 54% since 2025, partly supported by BD developments and key overseas Phase III trials. The bank expects that, as market sentiment toward

AASTOCKSSep 9 12:08

Novo-Nordisk A/S: Late-stage trials show semaglutide can reduce childhood obesity rates

Novo-Nordisk A/S stated that in a late-stage trial, 40.4% of children aged 6 to under 12 treated with semaglutide, the active ingredient in its weight-loss drug Wegovy, were no longer classified as obese after 68 weeks. All participants underwent lifestyle modifications throughout the trial, including reduced caloric intake and increased physical activity. Novo-Nordisk A/S indicated that the trial met its primary endpoint, demonstrating that the group receiving once-weekly subcutaneous injections of semaglutide achieved significantly greater weight reduction at week 68 compared to the placebo group. The overall safety and tolerability of semaglutide

AASTOCKSSep 8 09:48

Akeso Biopharma (9926.HK): Rapid Expansion of IO 2.0 Combination Therapies; Strong Momentum from Three Key Growth Engines

Event: The company announced its 2026 semi-annual report. Revenue for the first half of 2026 reached RMB 1.806 billion (+27.9%), comprising commercial sales revenue of RMB 1.803 billion (+28.7%) and commercial licensing revenue of RMB 2.5 million. Net profit

China Post SecuritiesSep 7 14:51

CLSA: Fundamentals of China's biotechnology sector remain solid; top picks are BeiGene (06160), Innovent Bio (01801), and WeLiShengBo (09887).

CLSA believes that sentiment in China's biotechnology sector has not yet fully reflected fundamental progress, and high-quality biotech companies with attractive valuations remain well-positioned as sentiment normalizes.

Zhitong FinanceSep 7 09:52